Opsona Therapeutics Limited, a Dublin, Ireland-based innate immune drug development company, raised €3m (US$4m) in a second closing of its Series C equity financing.
New investor Omnes Capital provided the funding, which brings the total raised in the Series C round to €36m (US $48.6m). On April 25th, 2013, Opsona had raised €33m (US$43m) from Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund, Seroba-Kernel Life Sciences, BB Biotech Ventures, Sunstone Capital, Baxter Ventures, Amgen Ventures and EMBL Ventures (read the news here).
The company intends to use the proceeds to fund a three-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of its lead product OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical indication for the development of OPN-305.
Its lead product is a humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which has demonstrated activity in a number of animal models and was recently tested in a phase I clinical trial in healthy volunteers and in a pilot cohort of renal transplant recipients.
founded in 2004 and led by Dr. Martin Welschof, CEO, Opsona focuses on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer’s disease and atherosclerosis.